Name: Tina Nova
Current Company: Genoptix Medical Laboratory
Title: Co-founder and CEO
Profile: Tina S. Nova, Ph.D., is president and CEO of the molecular diagnostics company Genoptix, a position she has held since 2000. Oncologists who specialize in blood cancers send their samples to the company, which then uses its diagnostic capabilities to rapidly determine the best course of treatment for the patient. The company has been profitable since 2007, and Forbes ranked Genoptix 15th on its 2009 list of the growing companies. The company believes it can capture 15 percent of the bone marrow testing market by 2015--nearly double its current market share of 8 percent.
Prior to her involvement it Genoptix, Nova was CEO of Nanogen and also did a stint as CEO of Selective Genetics. She currently serves as a member of the board of directors of Arena Pharmaceuticals and Cypress Bioscience. She holds a B.S. degree in Biological Sciences from the University of California, Irvine and a Ph.D. in Biochemistry from the University of California, Riverside.